Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.
about
Targeting mTOR signaling pathways and related negative feedback loops for the treatment of acute myeloid leukemia.N-(2-Hydroxypropyl)methacrylamide Copolymer-Drug Conjugates for Combination Chemotherapy of Acute Myeloid LeukemiaLow dose of lenalidmide and PI3K/mTOR inhibitor trigger synergistic cytoxicity in activated B cell-like subtype of diffuse large B cell lymphoma.Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang.Targeting the PI3K/AKT pathway via GLI1 inhibition enhanced the drug sensitivity of acute myeloid leukemia cells.Understanding of leukemic stem cells and their clinical implications.Novel B55α-PP2A mutations in AML promote AKT T308 phosphorylation and sensitivity to AKT inhibitor-induced growth arrest.Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer.Rictor has a pivotal role in maintaining quiescence as well as stemness of leukemia stem cells in MLL-driven leukemia.Targeting the mTOR Pathway in Leukemia.Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia.New insights into the Shwachman-Diamond Syndrome-related haematological disorder: hyper-activation of mTOR and STAT3 in leukocytes.The new and recurrent FLT3 juxtamembrane deletion mutation shows a dominant negative effect on the wild-type FLT3 receptor.hnRNPM guides an alternative splicing program in response to inhibition of the PI3K/AKT/mTOR pathway in Ewing sarcoma cells.Dual targeting of eIF4E by blocking MNK and mTOR pathways in leukemia.The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias.Mutation in the FGFR1 tyrosine kinase domain or inactivation of PTEN is associated with acquired resistance to FGFR inhibitors in FGFR1-driven leukemia/lymphomas.Modes of Interaction of KMT2 Histone H3 Lysine 4 Methyltransferase/COMPASS Complexes with Chromatin.
P2860
Q36214081-DB6BF362-C7B1-4435-B89D-63EAB24A3FA0Q36722841-0BB82182-2E59-437F-B719-B6665FAC6EC6Q36725307-DF29F8D4-F892-4A12-A5F4-92E934BB55A8Q37094051-69FDA3D1-A2DF-418C-A575-6CF5BCB3C4AAQ37591262-522967A9-BBD1-43D8-9437-C48B3A75F107Q37616010-AC0140D7-6843-4C93-A57B-559D04BC4968Q37641562-33A16248-9CA2-4146-812B-8658126EC896Q38381981-ABB36AD1-3486-4E7F-95CF-EEEA702E7F58Q38743320-15BDA319-35D7-44BC-9476-144534C7153CQ38753222-12C38919-263C-4B08-AAE0-B2D3900A8121Q38790630-B2B6C01F-99CF-42AD-94B0-78815BE0C18CQ39326047-52062DAD-C393-4EC4-80AC-C94288AA1BF7Q41163641-B7267854-901D-4BB1-B56C-77E2CB13C3EDQ42534044-AF3782EF-6920-41F9-B367-8EBA26A25187Q47116845-D59DAB9B-EBB0-472E-B188-BB9970A243BAQ48057652-3C1BAF07-8C74-46C6-86D0-825952D6990AQ48151269-0EAA9380-8214-416B-B735-79DD5D1456C8Q48227433-A72C4FDF-40F9-4110-A30B-AB588BEE35F1Q52369540-4F4A4E50-5816-4264-9C90-0B22EC8A611B
P2860
Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Dual PI3K/mTOR inhibition show ...... ranged acute myeloid leukemia.
@en
Dual PI3K/mTOR inhibition show ...... ranged acute myeloid leukemia.
@nl
type
label
Dual PI3K/mTOR inhibition show ...... ranged acute myeloid leukemia.
@en
Dual PI3K/mTOR inhibition show ...... ranged acute myeloid leukemia.
@nl
prefLabel
Dual PI3K/mTOR inhibition show ...... ranged acute myeloid leukemia.
@en
Dual PI3K/mTOR inhibition show ...... ranged acute myeloid leukemia.
@nl
P2093
P2860
P50
P356
P1433
P1476
Dual PI3K/mTOR inhibition show ...... ranged acute myeloid leukemia.
@en
P2093
K Spiekermann
M Rothenberg
M Subklewe
N Sandhöfer
P2860
P2888
P304
P356
10.1038/LEU.2014.305
P577
2014-10-17T00:00:00Z